Clinical trials
Advanced Tumors clinical trials
Below are recruiting advanced tumors clinical trials, each written for real people, not researchers. We’re tracking 1,354 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06598371RecruitingPhase 1/Phase 2
Study of engineered immune cells for advanced solid tumors
This trial tests a new treatment made from your own immune cells (called tumor-infiltrating lymphocytes) that are genetically modified to fight cancer better. It is for people with certain advanced solid tumors that have not responded well to other treatments.
Houston, TexasAges 18 years+ - NCT06911827RecruitingPhase 1/Phase 2
Combination drug study for advanced solid tumor cancer
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT06350006RecruitingPhase 1
Testing SHR-A1904 combinations for CLDN18.2-positive advanced tumors
This study tests an experimental drug combination for people with advanced solid tumors that have a specific protein called CLDN18.2. It aims to see if the combination works better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT06512116RecruitingPhase 1
Testing SIBP-A17 for advanced solid tumors with HER2
This trial tests a new drug called SIBP-A17 for advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a protein called HER2, and the goal is to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT06178614RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT06667141RecruitingPhase 1
Study of ACR-2316 for advanced solid tumors
This study tests a new targeted drug called ACR-2316 for people with specific advanced solid tumors that have already been treated but are no longer responding. It aims to see how well the drug works and how safe it is, while looking for a tumor that has certain markers (like a protein or genetic change) that may make the drug more effective.
Phoenix, ArizonaAges 18 years+ - NCT07617727RecruitingPhase 1
A study of an experimental drug for advanced solid tumors
This trial tests a new drug, JSKN021, for people with advanced solid tumors that have not responded to standard treatments, are not tolerated to them, or have no standard options. The goal is to see if the drug is safe and effective in treating these cancers.
Fuzhou, FujianAges 18–75 - NCT06464055RecruitingPhase 1/Phase 2
A study of GQ1010 for advanced solid tumors
This trial tests a new drug called GQ1010 for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets a protein called Trop-2 on cancer cells to try to shrink tumors or slow their growth.
BeijingAges 18 years+ - NCT05819684RecruitingPhase 1
First testing of SHR-4602 for HER2-positive solid tumors
This Phase 1 study tests a new medicine called SHR-4602 in people with advanced solid tumors that have HER2 changes. It is for cases where standard treatments have not worked, cannot be tolerated, or are not available.
Guangzhou, GuangdongAges 18–75 - NCT07639450RecruitingPhase 1/Phase 2
N-3C01 Cancer Treatment Study for Advanced Solid Tumors
This trial tests a new drug called N-3C01, alone or combined with immune-boosting medications, in patients whose advanced cancer has stopped responding to standard treatments. The goal is to see if this approach can slow or shrink tumors that have become resistant to other therapies.
Saint Leonards, New South WalesAges 18–75 - NCT07045454RecruitingPhase 1
MHB118C shot for advanced solid tumors
This trial tests an injection called MHB118C for people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The goal is to see if this new drug can help shrink tumors or slow their growth.
ShanghaiAges 18 years+ - NCT07524348RecruitingPhase 1
Safety Study of E303 Drug in Advanced Solid Tumors
This early-stage trial tests whether a new drug called E303 is safe for patients with advanced solid cancers (tumors that have spread or returned). Researchers want to find the right dose and watch for side effects.
Scottsdale, ArizonaAges 18 years+ - NCT06718946RecruitingEarly Phase 1
IV IDOV-SAFE for advanced solid tumors: safety and effect study
This trial tests a new drug called IDOV-SAFE given through a vein. It is for people with advanced solid tumors that have not responded to standard treatments. The study aims to see if the drug is safe and if it can help shrink tumors.
ShanghaiAges 18–75 - NCT06376136RecruitingPhase 1/Phase 2
Combination therapy for advanced HER2-positive cancers
This trial tests a new combination of two drugs, BAT8010 and BAT1006, for people with advanced solid tumors that have HER2 expression. It aims to see if this combination is safe and effective for those who have run out of standard treatment options.
Guangzhou, GuangdongAges 18 years+ - NCT07326488RecruitingPhase 1/Phase 2
Study of MHB009C for advanced solid tumors
This trial tests a new drug called MHB009C for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07293754RecruitingPhase 1/Phase 2
Study of RPTR-1-201 for advanced solid tumors
This trial tests a new drug called RPTR-1-201 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT07192107RecruitingPhase 1/Phase 2
Study of MHB042C for advanced solid tumors
This trial tests a new drug called MHB042C for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective.
Guangzhou, GuangdongAges 18 years+ - NCT07368127RecruitingPhase 1
Study of TPD3310 for advanced solid tumors
This trial tests an experimental drug called TPD3310 for people with advanced solid tumors (like lung, stomach, liver, or other cancers) that have worsened after standard treatments or cannot tolerate them. It aims to see if the drug is safe and works, especially for tumors with a specific marker called c-MET.
Beijing, Beijing MunicipalityAges 18–75 - NCT04777994RecruitingPhase 1
Drug ABBV-CLS-484 for advanced cancers that lack options
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
Tucson, ArizonaAges 18 years+ - NCT06717750RecruitingPhase 1
Study of a new drug for advanced solid tumors
This early-phase trial tests a new oral drug (CSCJC3456) for people with advanced solid tumors, especially those with certain FGFR gene changes. It aims to see if the drug is safe and may help when other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT07404332RecruitingPhase 1
Combination therapy for tumors resistant to immunotherapy
This trial tests a combination of two drugs (5-Azacitidine and a PD-1/PD-L1 inhibitor) for people whose solid tumors stopped responding to standard PD-1/PD-L1 immunotherapy alone. The goal is to see if this new combination can help shrink the tumor or slow its growth.
Iowa City, IowaAges 18–99 - NCT06726148RecruitingPhase 1/Phase 2
Study of ECI830 for advanced breast cancer and solid tumors
This trial is testing a new drug called ECI830, either alone or with another drug, for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. It may be an option if you have HR+/HER2- breast cancer, small cell lung cancer, or a tumor with a specific gene change (CCNE1 amplification).
Los Angeles, CaliforniaAges 18–100 - NCT05752552RecruitingPhase 1
Safety study of a MET-targeting pill for advanced lung cancer
This Phase 1 trial tests DO-2 to see how safe it is and how the body absorbs it (pharmacokinetics) in people with advanced or metastatic lung cancer. It is for tumors that have a specific MET exon 14 “skipping” mutation and for whom standard treatments are no longer an option.
BrusselsAges 18 years+ - NCT07288359RecruitingPhase 1/Phase 2
Study of GVV858 for HR+/HER2- breast cancer and other solid tumors
This trial is testing a new drug, GVV858, either alone or with hormone therapy, for people with HR+/HER2- advanced breast cancer or certain other advanced solid tumors. It may be an option if standard treatments are no longer working or available.
Atlanta, GeorgiaAges 18 years+
Hear when a new Advanced Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced tumors?
- Yes. Clin2 currently lists 1,354 recruiting advanced tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Solid Tumors
- Advanced Malignant Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.